BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2017-05-23 05:00 |
BerGenBio ASA: Results for the First Quarter 2017
|
English | 54.1 KB | ||
| 2017-05-23 05:00 |
BerGenBio ASA: Results for the First Quarter 2017
|
English | 489.5 KB | ||
| 2017-05-23 05:00 |
BerGenBio ASA: Results for the First Quarter 2017
|
English | 4.7 MB | ||
| 2017-05-23 05:00 |
BerGenBio ASA: Results for the First Quarter 2017
|
English | 6.6 KB | ||
| 2017-05-22 06:00 |
BerGenBio Announces Start of Randomised Phase I/II Trial Assessing Selective AX…
|
English | 8.6 KB | ||
| 2017-05-19 06:00 |
Abstract showing activity in MDS of BerGenBio's first-in-class AXL inhibitor, B…
|
English | 4.0 KB | ||
| 2017-05-16 06:00 |
BerGenBio ASA: First Quarter 2017 Results Presentation and Webcast
|
English | 3.0 KB | ||
| 2017-05-08 06:36 |
BerGenBio ASA - Stabilisation notice
|
English | 7.8 KB | ||
| 2017-04-07 06:20 |
Oslo Børs - BerGenBio ASA - New security will be listed 07.04.2017
|
English | 804 bytes | ||
| 2017-04-07 06:00 |
BerGenBio ASA - Stabilisation and over-allotment notice
|
English | 10.6 KB | ||
| 2017-04-06 14:44 |
Financial calendar
|
English | 659 bytes | ||
| 2017-04-06 12:17 |
Oslo Børs - BerGenBio ASA - New security is quoted as from 07.04.2017
|
English | 813 bytes | ||
| 2017-04-06 09:19 |
BerGenBio ASA - INCREASE IN SHARE CAPITAL
|
English | 8.9 KB | ||
| 2017-04-06 08:09 |
Flagging BerGenBio
|
Norwegian | 599 bytes | ||
| 2017-04-06 06:38 |
BerGenBio ASA - Allocation to primary insiders
|
English | 10.0 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
